Study Stopped
Due to poor patient enrollment
Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients
FORUM
2 other identifiers
observational
150
1 country
43
Brief Summary
The purpose of this study is to identify which patients, receiving Faslodex within the approved label, benefit most from Faslodex treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2005
Longer than P75 for all trials
43 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2005
CompletedFirst Submitted
Initial submission to the registry
October 18, 2005
CompletedFirst Posted
Study publicly available on registry
October 19, 2005
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2009
CompletedApril 22, 2009
April 1, 2009
October 18, 2005
April 21, 2009
Conditions
Keywords
Eligibility Criteria
You may qualify if:
- Postmenopausal
- Locally advanced or metastatic hormone sensitive breast cancer with known estrogen receptor (ER) and progesterone receptor (PR) status
- Patient had a recurrence during or after adjuvant anti-oestrogen treatment or progression of the disease during anti-oestrogen treatment
You may not qualify if:
- Life threatening metastases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (43)
Research Site
Alkmaar, Netherlands
Research Site
Almelo, Netherlands
Research Site
Almere Stad, Netherlands
Research Site
Amsterdam, Netherlands
Research Site
Apeldoorn, Netherlands
Research Site
Assen, Netherlands
Research Site
Bergen op Zoom, Netherlands
Research Site
Capelle aan den IJssel, Netherlands
Research Site
Delft, Netherlands
Research Site
Delfzijl, Netherlands
Research Site
Doetinchem, Netherlands
Research Site
Dokkum, Netherlands
Research Site
Dordrecht, Netherlands
Research Site
Drachten, Netherlands
Research Site
Ede Gld, Netherlands
Research Site
Eindhoven, Netherlands
Research Site
Geldrop, Netherlands
Research Site
Gorinchem, Netherlands
Research Site
Hardenberg, Netherlands
Research Site
Heerenveen, Netherlands
Research Site
Heerlen, Netherlands
Research Site
Hellevoetsluis, Netherlands
Research Site
Hilversum, Netherlands
Research Site
Hoogeveen, Netherlands
Research Site
Leiden, Netherlands
Research Site
Leiderdorp, Netherlands
Research Site
Leidschendam, Netherlands
Research Site
Meppel, Netherlands
Research Site
Nieuwegein, Netherlands
Research Site
Oss, Netherlands
Research Site
Roermond, Netherlands
Research Site
Rotterdam, Netherlands
Research Site
Stadskanaal, Netherlands
Research Site
Terneuzen, Netherlands
Research Site
The Hague, Netherlands
Research Site
Tilburg, Netherlands
Research Site
Utrecht, Netherlands
Research Site
Vlaardingen, Netherlands
Research Site
Winschoten, Netherlands
Research Site
Winterswijk, Netherlands
Research Site
Zeist, Netherlands
Research Site
Zevenaar, Netherlands
Research Site
Zwolle, Netherlands
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
AstraZeneca Netherlands Medical Director, MD
AstraZeneca
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
October 18, 2005
First Posted
October 19, 2005
Study Start
June 1, 2005
Study Completion
December 1, 2009
Last Updated
April 22, 2009
Record last verified: 2009-04